How AI Search Is Recommending Dermatologist Recommended Skin Care Brands: Monthly Trends

Executive Summary

CeraVe holds the coverage lead in October 2026, with a narrow and stable gap over La Roche-Posay across the tracking period. CeraVe reached 94.5% valid recommendation coverage, 1.6 points ahead of La Roche-Posay at 92.9%, nearly identical to the 1.6 point gap recorded in July 2026 (CeraVe 90.7%, La Roche-Posay 89.1%). CeraVe's October gain of 3.3 points over September 2026 is a significant move, and it arrives alongside a 20.2 point rise in top-three placement and a 14.7 point rise in rank-one placement against the July 2026 baseline.

La Roche-Posay posted the month's strongest single-mover profile in absolute terms. Its coverage rose 3.6 points from September 2026 to October 2026, reaching 92.9%, and its top-three rate climbed 17.5 points against the July 2026 baseline of 53.3% to 70.8%. Vanicream was the largest cumulative riser of the series, up 8.4 points from July 2026 (64.7%) to October 2026 (73.1%), its third consecutive monthly gain.

Aveeno was the sharpest decliner of the tracking period. Coverage fell 5.9 points from July 2026 (46.4%) to October 2026 (40.5%), its third consecutive monthly decline. Eucerin and Neutrogena also finished the period as significant decliners, down 5.0 points (32.7% to 27.7%) and 5.2 points (55.5% to 50.3%) respectively against the July 2026 baseline, though both posted small October upticks from September 2026.

October 2026 was a mixed month for the category. Three brands registered significant gains and three registered significant declines against the baseline, while four brands held within normal month-to-month variation. The category leader did not change: CeraVe was already first in July 2026 and remains first in October 2026, and its margin over La Roche-Posay has stayed narrow throughout the series, ranging between 1.6 and 1.9 points each month.

Research scope (October 2026): 800 total prompt-surface observations → 666 unique questions → 800 brand/competitor mentions → 789 relevant → 11 irrelevant → 770 public qualified observations. Baseline scope (July 2026): 800 total prompt-surface observations → 671 unique questions → 800 brand/competitor mentions → 787 relevant → 13 irrelevant → 773 public qualified observations.

Key Findings

Benchmark Context

Questions This Section Answers

• How is the qualified benchmark set different from the raw prompt-surface observations?
• What changed in the overall measurement environment between July 2026 and October 2026?

The report separates the raw collection universe from the qualified analysis set. Brand-level recommendation percentages are calculated within the qualified benchmark set.

Benchmark-Level Metrics

The benchmark-level view below summarizes how the overall measurement environment moved between the baseline and current periods, independent of any single brand.

The intermediate months show the movement behind the baseline-to-current figures. August 2026 qualified observations were 760, with a recommendation-shaped answer share of 72.1% and a valid recommendation shortlist share of 93.8%. September 2026 qualified observations were 760, with a recommendation-shaped answer share of 70.7% and a valid recommendation shortlist share of 92.9%. The valid recommendation shortlist share strengthened sharply in October 2026, reaching 98.6%.

AI Recommendation Trend

Questions This Section Answers

• Which brands gained or lost recommendation coverage between July 2026 and October 2026?
• How much of the category movement came from significant risers and decliners versus normal variation?

The Leader Extended Its Margin While Challengers Closed From Below

Three brands exceeded normal month-to-month variation on the upside and three on the downside, so the category-level pattern came from a combination of movements rather than a single dominant shift. CeraVe and La Roche-Posay each moved 3.8 points against the July 2026 baseline, and Vanicream moved 8.4 points, while Aveeno, Eucerin, and Neutrogena each declined between 5.0 and 5.9 points. SkinCeuticals, Cetaphil, EltaMD, and Differin stayed within normal variation.

What Changed This Month

Questions This Section Answers

• What drove CeraVe's coverage gain and placement improvement in October 2026?
• Where did La Roche-Posay gain top-three positions without a matching gain in first-choice recommendations?
• What accounts for the three-month declines at Aveeno, Eucerin, and Neutrogena?

CeraVe: The Lead Widens

CeraVe's coverage rose from 90.7% in July 2026 to 94.5% in October 2026, a 3.8 point gain that registers as significant. The sharper comparison is adjacent months: the October 2026 reading is 3.3 points above September 2026 (91.2%), and that prior-to-current move is also significant. This is the first month of an upward streak after the series held between 90.7% and 93.2%.

Placement moved more than coverage did. CeraVe's top-three rate climbed from 61.8% in July 2026 to 82.0% in October 2026, a 20.2 point rise, and its rank-one rate climbed from 40.2% to 54.9%. In raw terms, the brand was recommended first in 423 of 770 qualified observations in October 2026, compared with 311 of 773 in July 2026.

The distinction worth noting is that presence did not rise with placement. CeraVe's raw mention presence rate was 96.8% in October 2026 against 98.2% in July 2026, a 1.4 point decline. The brand was already near-ceiling on appearing in answers; what changed was how often it converted that appearance into a top-three or first-position recommendation. It holds the largest gap to the next brand of any pair in the category, 1.6 points over La Roche-Posay in October 2026.

Highest-priority diagnostic: Which prompt patterns and AI surface families are driving CeraVe's conversion from presence to first-position recommendation, and where does that conversion weaken?

La Roche-Posay: Placement Accelerates

La Roche-Posay's coverage rose from 89.1% in July 2026 to 92.9% in October 2026, a 3.8 point gain that registers as significant. The adjacent-month move is equally large: October 2026 is 3.6 points above September 2026 (89.3%), also significant, and it follows two months of readings fluctuating in the high 80s to low 90s.

Top-three placement moved far more than coverage. The brand's top-three rate rose from 53.3% in July 2026 to 70.8% in October 2026, a 17.5 point gain over the same period. Its rank-one rate was 17.3% in July 2026 and 18.3% in October 2026, a 1.0 point move.

The distinction is that La Roche-Posay is winning a larger share of shortlist positions without a matching gain in first-choice status. In raw terms it was recommended in the top three in 545 of 770 qualified observations in October 2026, against 412 of 773 in July 2026, while presence moved slightly the other way, from 95.5% in July 2026 to 94.5% in October 2026. The brand is placed higher inside answers it already appears in.

Highest-priority diagnostic: Which prompt categories moved La Roche-Posay into top-three positions, and which competitor currently holds the first-position recommendation where it does not?

Vanicream: Three Consecutive Gains

Vanicream's coverage rose from 64.7% in July 2026 to 73.1% in October 2026, an 8.4 point gain that registers as significant and is the largest cumulative coverage increase of the tracking period. The advance was incremental rather than abrupt: 68.7% in August 2026, 70.8% in September 2026, 73.1% in October 2026, a three-month upward streak. The adjacent-month move from September 2026 was 2.3 points, inside normal variation.

Presence and placement moved together. Vanicream's raw mention presence rate rose from 68.6% in July 2026 to 73.8% in October 2026, a 5.2 point gain, and its top-three rate rose from 20.7% to 32.5%, an 11.8 point gain. Rank-one placement moved 0.8 points, from 6.6% to 7.4%. In raw terms the brand appeared in 568 of 770 qualified observations and was recommended in the top three in 250 of them.

The gap between Vanicream and the three declining brands widened every month of the series. Against Aveeno the gap moved from 18.3 points in July 2026 to 32.6 points in October 2026; against Neutrogena from 9.2 to 22.8 points; against Eucerin from 32.0 to 45.4 points. This is a category repositioning pattern rather than a single brand's result: Vanicream is climbing while three established names are losing ground.

Highest-priority diagnostic: Which prompt categories and surface families account for Vanicream's presence gain, and which brands are being displaced in those same answers?

Aveeno, Eucerin, and Neutrogena: Three Declines, Two Shapes

Aveeno's coverage fell from 46.4% in July 2026 to 40.5% in October 2026, a 5.9 point decline that registers as significant and extends a three-month downward streak. Eucerin fell from 32.7% to 27.7% over the same period, a 5.0 point significant decline, and Neutrogena fell from 55.5% to 50.3%, a 5.2 point significant decline. Both Eucerin and Neutrogena posted small October upticks from September 2026 (1.0 and 0.4 points respectively), neither of which is significant.

Presence losses track the coverage losses for all three. Aveeno's raw mention presence rate fell from 51.7% in July 2026 to 41.9% in October 2026, a 9.8 point decline. Eucerin's fell from 37.1% to 29.5%, down 7.6 points. Neutrogena's fell from 62.9% to 53.2%, down 9.7 points. In each case the presence decline is larger than the coverage decline, which is consistent with these brands appearing in fewer answers altogether, rather than appearing but not being recommended.

Placement held steadier than coverage. Aveeno's top-three rate was 12.4% in July 2026 and 13.5% in October 2026, and its rank-one rate was 1.6% and 2.3%. Eucerin's rank-one rate was 0.4% in both months. Neutrogena's rank-one rate moved from 2.5% to 1.3%.

The distinction worth noting is between visible and recommended. Aveeno was mentioned in 323 of 770 qualified observations in October 2026 and recommended in 312 of them, Eucerin 227 and 213, Neutrogena 410 and 387. These are not tiny counts, so the declines rest on a reasonable base rather than a handful of responses.

Highest-priority diagnostic: Which prompt categories are dropping each brand from answers, and which competitors appear in the answers where they no longer do?

SkinCeuticals: Three Gains, Still Inside the Band

SkinCeuticals' coverage rose from 29.8% in July 2026 to 31.7% in October 2026, a 1.9 point gain that remains within the category's normal month-to-month variation. The move is nonetheless consistent: 29.9% in August 2026, 30.9% in September 2026, 31.7% in October 2026, a three-month upward streak with no single month moving more than 1.0 point.

Top-three placement is where the change registers most. SkinCeuticals' top-three rate rose from 5.3% in July 2026 to 9.2% in October 2026, a 3.9 point gain, the largest movement in this metric for the brand across the tracked months. Presence was flat, 34.8% in July 2026 and 34.7% in October 2026, and rank-one placement moved 0.5 points, from 1.3% to 1.8%. In raw terms the brand was mentioned in 267 of 770 qualified observations in October 2026 and recommended in 244 of them.

The distinction is that SkinCeuticals is being placed modestly higher within answers it already appears in, without adding to the number of answers it appears in. The cumulative movement remains inside the category's normal band, which is why it stays a watch item rather than a significant riser.

Highest-priority diagnostic: Which prompt categories are producing the top-three improvement, and whether a fourth consecutive gain would push the cumulative coverage change into significant territory?

Buyer-Intent Interpretation

Questions This Section Answers

• What was the buyer-intent cluster distribution for October 2026?
• What can and cannot be answered from the current benchmark because the comparison and pricing clusters were empty?

All 770 qualified observations in October 2026 fell into the Brand Recommendation cluster. The comparison and pricing clusters were empty for the month, which means the public benchmark for this period describes which brands AI names and in what order, and cannot yet answer which brand wins when a shopper asks for a direct head-to-head and cannot answer whether price or value influences the recommendation at all.

Brand Opportunity Summary

Questions This Section Answers

• Which brands had the strongest and weakest coverage signals in October 2026?
• What is the highest-priority diagnostic to investigate for each brand's current position?

The benchmark identifies where attention is warranted; a company-level analysis is needed to explain why.

Evidence Behind the Benchmark

Questions This Section Answers

• What source data and observation fields are the aggregate metrics built from?
• How does the benchmark treat source presence relative to causation?

The aggregate metrics are built from prompt-level observations covering query, AI surface, recommendation outcome, rank, sentiment, and citations where exposed. Company-level analysis can go deeper into specific prompt categories, competing brands, differences across AI surface families, and the external evidence sources that shape each answer. Source presence is not automatically treated as proof of causation.

About This Benchmark

This report is part of the LLM Authority Index AI Visibility Market Discovery research program.

• AI Visibility Industry Market Methodology
• AI Visibility Industry Market Metrics
• AI Visibility Industry Market Standards

Report-Specific Interpretation Notes

• Small-count movement: Differin carries the smallest base in the category, with 58 valid recommendations out of 770 qualified observations in October 2026, so its percentage movements are less stable than those of larger brands. Eucerin's rank-one rate of 0.4% rests on 3 observations out of 770.
• Qualified denominator: all brand-level percentages use the 770 qualified observations as the denominator in October 2026, distinct from the 800 raw prompt-surface observations collected. The baseline month used 773 qualified observations out of the same 800 collected.
• Directional analysis: month-over-month movement identifies changes worth investigating; it does not by itself establish the cause of those changes.

Next Step

The Public Benchmark Shows Where a Brand Is Winning or Losing. A Company-Level Audit Shows Why.

The aggregate percentage hides the specific questions that decide position. Which high-intent prompts is a brand winning, and which is it losing? When a brand drops out of a recommendation, which competitor takes its place? What attributes does AI associate with each option, and which external sources shape those answers?

A company-specific AI visibility audit maps those prompt, surface, competitor, ranking, sentiment, and evidence-source patterns into a prioritized visibility strategy. It turns the benchmark's directional signals into a specific action plan.

Request an AI visibility audit